Hutch News

Six researchers receive $3.5 million in grants from Kuni Foundation

Six researchers receive $3.5 million in grants from Kuni Foundation

Funds will support innovative high-risk/high-reward projects across Fred Hutchinson Cancer Center/University of Washington/Seattle Children’s Cancer Consortium with the potential to revolutionize care
Hutch News - February 27, 2023
Merkel cell carcinoma researcher Dr. Nick Salisbury named Brave Fellow

Merkel cell carcinoma researcher Dr. Nick Salisbury named Brave Fellow

Rare skin cancer is focus of work by Fred Hutch scientist who will receive support honoring runner Gabe Grunewald
Hutch News - October 06, 2022
Enhance, enhance! Computational tool “BayesSpace” zooms in to fine-map spatial transcriptomics

Enhance, enhance! Computational tool “BayesSpace” zooms in to fine-map spatial transcriptomics

From the Gottardo, Bielas, and Nghiem Labs, Biostatistics and Computational Biology Program, Cancer Consortium
Science Spotlight - March 21, 2022
Pembrolizumab treatment for Merkel cell carcinoma

Pembrolizumab treatment for Merkel cell carcinoma

From the Nghiem Laboratory, Clinical Research Division
Science Spotlight - March 18, 2019
Seattle team pivotal to FDA OK on drug for rare skin cancer

Seattle team pivotal to FDA OK on drug for rare skin cancer

UW Medicine and Fred Hutch had key roles in clinical trial of immunotherapy option for often-lethal Merkel cell cancer
News Releases - December 20, 2018
Triple therapy for rare skin cancer shows promise in small, early-stage trial

Triple therapy for rare skin cancer shows promise in small, early-stage trial

Combo of T-cell therapy, newly FDA-approved drug and another immune booster kept cancer at bay for three of four patients with metastatic Merkel cell carcinoma
Hutch News - May 31, 2017
With immunotherapy trial, ‘a real paradigm shift’ in rare skin cancer

With immunotherapy trial, ‘a real paradigm shift’ in rare skin cancer

Investigators report ‘extraordinarily’ long-lasting treatment responses in patients with chemo-resistant, metastatic Merkel cell carcinoma
Hutch News - April 03, 2017
Immunotherapy drug becomes first therapy approved by FDA for rare skin cancer

Immunotherapy drug becomes first therapy approved by FDA for rare skin cancer

Benefit seen in nearly one-third of patients ‘with no hope at all of surviving’ their treatment-resistant Merkel cell carcinoma
Hutch News - March 24, 2017